On September 30, 2026, the United States Court of Appeals for the Third Circuit revived a putative securities fraud class action against Ocugen, Inc., a small, publicly traded pharmaceutical company, holding that a stock’s rapid price recovery after a corrective disclosure cannot, on its own, prove that an earlier misstatement was immaterial. In re Ocugen, Inc. Securities Litigation, No. 25-2653 (3d Cir. Sept. 30, 2026). The decision abrogates what the court itself labeled the “Oran-Burlington rule,” a line of Third Circuit precedent stretching back nearly 30 years. For practitioners defending or bringing Section 10(b) claims in Pennsylvania, New Jersey, or Delaware federal courts, the ruling removes a familiar tool from the motion-to-dismiss toolkit and replaces it with a more fact-intensive materiality inquiry.
What Happened in Ocugen
The plaintiffs alleged that Ocugen and its chief executive officer made false and misleading statements about the company’s finances and internal accounting controls, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The complaint described an unusually detailed internal paper trail: a financial planning manager and a department head reportedly authored a 20-page report flagging what the complaint called “manipulated numbers” being shared with the public, and the company’s chief financial officer allegedly told a colleague he had uncovered “multiple things that were wrong and the Company was misleading the public.” According to the complaint, when a quarterly report came due, the CFO refused to sign it and was terminated, as was a vice president of finance who also declined to sign. Ocugen later disclosed that it would restate roughly 15 quarters of financial statements, acknowledging they were “materially misstated” and “should no longer be relied on,” with current liabilities understated by as much as 45.1% in certain periods.
Ocugen’s stock price dropped more than 10% the day after the restatement announcement but recovered within two trading days. The district court treated that quick rebound as dispositive of immateriality and dismissed the case, relying on circuit precedent holding that a stock price’s return to its prior level after a corrective disclosure forecloses a finding of materiality as a matter of law.
A Brief History of the Materiality Standard
The materiality element of a securities fraud claim has a long pedigree, and the Third Circuit’s opinion traces that lineage carefully. The Supreme Court first articulated the modern materiality test in the proxy-solicitation context, holding that “an omitted fact is material if there is a substantial likelihood that a reasonable shareholder would consider it important in deciding how to vote,” and that the standard requires “a substantial likelihood that the disclosure of the omitted fact would have been viewed by the reasonable investor as having significantly altered the ‘total mix’ of information made available.” TSC Industries, Inc. v. Northway, Inc., 426 U.S. 438, 449 (1976). The court was careful not to set too low a bar, cautioning that an overly inclusive standard could lead management to “bury the shareholders in an avalanche of trivial information.”
In 1988, the Supreme Court extended the TSC Industries “total mix” standard to claims under Section 10(b) and Rule 10b-5, expressly adopting it for that context and rejecting a bright-line “agreement-in-principle” test that some circuits had used to decide when preliminary merger talks became material. Basic Inc. v. Levinson, 485 U.S. 224, 231-32, 236 (1988). The court explained that “any approach that designates a single fact or occurrence as always determinative of an inherently fact-specific finding such as materiality, must necessarily be overinclusive or underinclusive.” That rejection of categorical, one-size-fits-all materiality rules became the throughline for decades of subsequent case law.
The Supreme Court reinforced that same principle in 2011, rejecting a pharmaceutical company’s proposed rule that adverse event reports about a drug could never be material absent statistically significant evidence of causation. Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011). The court again emphasized that materiality “is a fact-specific inquiry” and that any bright-line substitute for that inquiry risks “artificially excluding” information a reasonable investor would otherwise find significant.
The Oran-Burlington Rule and Its Abrogation
Against that backdrop, the Third Circuit had developed its own shortcut: where a company’s stock price failed to move, or quickly recovered, after a corrective disclosure, courts in the circuit treated that market reaction as conclusive proof that the underlying misstatement was immaterial. The district court in Ocugen applied that rule to dismiss the case based on the stock’s two-day rebound.
The Third Circuit panel held that this approach could not survive the Supreme Court’s intervening materiality jurisprudence. The court reaffirmed that the governing test remains whether a misstatement or omission would have “significantly altered the total mix of information” available to reasonable investors at the time of their investment decisions, and it concluded that a stock-price-movement proxy is both underinclusive and overinclusive of that fact-specific inquiry. The panel accordingly abrogated the portions of its prior decisions that relied on the categorical rule, noting that no published Third Circuit opinion had actually applied the rule in the 20 years preceding this decision. The court vacated the dismissal and remanded the case to the Eastern District of Pennsylvania for a fresh materiality and scienter analysis unaided by the now-abrogated stock-price shortcut. The panel did affirm dismissal on one narrower point, concluding that the plaintiffs had not adequately alleged a duty to disclose further specifics about the CFO’s departure.
Why This Matters
The practical effect of the decision is to push materiality analysis in the Third Circuit back toward the multifactor, context-driven approach the Supreme Court has consistently required. Litigants can no longer rely on a quick post-disclosure stock rebound to end a case at the pleading stage; nor, by the same logic, could a severe price drop alone establish materiality without a broader total-mix analysis. District courts in Pennsylvania, New Jersey, and Delaware will need to engage with the full factual record, including the nature of the misstatement, the company’s own characterization of its significance, and the other circumstances surrounding disclosure, rather than treating market reaction as a substitute for that analysis.
The decision is also a useful reminder of how persistently the Supreme Court has pushed back against bright-line materiality rules generally, a theme that recurs from the proxy-disclosure context in 1976 through the Rule 10b-5 context in 1988 and the pharmaceutical-disclosure context in 2011. Companies and their counsel evaluating disclosure obligations, or defending securities suits in the Third Circuit, may want to revisit any pleadings or disclosure controls that assumed stock-price stability alone could insulate a statement from a materiality challenge.
Considering this shift, companies and their counsel operating in the Third Circuit may want to revisit disclosure controls and litigation strategy that previously leaned on post-disclosure stock performance as a safe harbor. A few areas worth evaluating: (i) issuers preparing restatements or corrective disclosures may want to document the total-mix analysis supporting a materiality conclusion rather than waiting to see how the market reacts; (ii) defendants currently litigating Section 10(b) claims in Pennsylvania, New Jersey, or Delaware federal courts may want to reassess any pending motion that relies on the Oran-Burlington rule, since that argument is no longer available; and (iii) companies evaluating whether a known error requires correction may want to apply the same reasonable-investor, total-mix framework the Third Circuit just reaffirmed, rather than a single quantitative or market-based proxy.
Contact Us
If you have any questions regarding this decision or its implications for your company’s securities fraud litigation strategy or disclosure practices, please contact Sarah Razaq Sallis, Jeff Le Riche, Kip Randall, or your Husch Blackwell attorney.